Publications & Reports

Hepatitis C.

Spearman CW, Dusheiko GM, Hellard M, Sonderup M
Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. Electronic address: wendy.spearman@uct.ac.za.

Abstract

Hepatitis C is a global health problem, and an estimated 71.1 million individuals are chronically infected with hepatitis C virus (HCV). The global incidence of HCV was 23.7 cases per 100 000 population (95% uncertainty interval 21.3-28.7) in 2015, with an estimated 1.75 million new HCV infections diagnosed in 2015. Globally, the most common infections are with HCV genotypes 1 (44% of cases), 3 (25% of cases), and 4 (15% of cases). HCV transmission is most commonly associated with direct percutaneous exposure to blood, via blood transfusions, health-care-related injections, and injecting drug use. Key high-risk populations include people who inject drugs, men who have sex with men, and prisoners. Approximately 10-20% of individuals who are chronically infected with HCV develop complications, such as cirrhosis, liver failure, and hepatocellular carcinoma over a period of 20-30 years. Direct-acting antiviral therapy is now curative, but it is estimated that only 20% of individuals with hepatitis C know their diagnosis, and only 15% of those with known hepatitis C have been treated. Increased diagnosis and linkage to care through universal access to affordable point-of-care diagnostics and pangenotypic direct-acting antiviral therapy is essential to achieve the WHO 2030 elimination targets.

Link to publisher’s web site32320-7 “”)

Publication

  • Journal: Lancet
  • Published: 19/10/2019
  • Volume: 394
  • Issue: 10207
  • Pagination: 1451-1466

Author